Occudo Quantitative Strategies LP Sells 5,057 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS)

Occudo Quantitative Strategies LP cut its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 32.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,692 shares of the company’s stock after selling 5,057 shares during the period. Occudo Quantitative Strategies LP’s holdings in Sensus Healthcare were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of SRTS. Ritholtz Wealth Management raised its stake in shares of Sensus Healthcare by 65.3% in the fourth quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock worth $355,000 after acquiring an additional 20,256 shares during the last quarter. Sigma Planning Corp bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $215,000. IFP Advisors Inc bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $95,000. Virtu Financial LLC bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $189,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $27,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Price Performance

SRTS opened at $4.46 on Monday. The company has a market cap of $73.57 million, a price-to-earnings ratio of 11.15 and a beta of 1.30. The firm has a 50 day simple moving average of $4.61 and a 200 day simple moving average of $6.12. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.20). The business had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, analysts expect that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital dropped their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.